Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,777.70up ₹16.70 (0.95%)BSE ₹1,778.25
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,761.00.
30 Oct: open ₹1,769.00, high ₹1,855.00, low ₹1,766.20
52-week range of traded prices to 30 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,26,530 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.90
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.78
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 51,30,21833.2% delivered
Sun Pharmaceutical Industries share news and announcements
1,452 announcements, routine notices left out, newest first. Page 25 of 30.
May 2011
14 May · Board meeting
Inter alia (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2011. (2) To consider the recommendation of payment of Dividend on equity shares for the year ended March 31, 2011 subject to the approval of the shareholders at the ensuing Annual General Meeting.
Apr 2011
1 Apr · Change in Company Secretary
Mr. Kamlesh Shah has resigned as Company Secretary of the Company with effect from April 1, 2011, and in his place Mr. Sunil Ajmera has been appointed as the Company Secretary cum Compliance Officer of the Company with effect from April 1, 2011.
Feb 2011
Jan 2011
31 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 45826 lacs for quarter ending on 31-DEC-2010 against Rs. 48964 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 34267 lacs for the quarter ending on 31-DEC-2010 against Rs. 31804 lacs for the quarter ending on 31-DEC-2009.31 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 160107 lacs for quarter ending on 31-DEC-2010 against Rs. 102086 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 35015 lacs for the quarter ending on 31-DEC-2010 against Rs. 33895 lacs for the quarter ending on 31-DEC-2009.18 Jan · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter / nine months ended December 31, 2010.
Dec 2010
6 Dec · Updates
On December 03, 2010, Sun Pharmaceutical Industries Ltd (Sun Pharma), and Sun Pharma Global (Sun Global, a wholly owned subsidiary of Sun Pharma) delivered a letter to Sun Pharma's U.S. subsidiary, Caraco's Board of Directors proposing a going-private transaction by which Sun Pharma, Sun Global and/or one or more of their affiliates would acquire all of the outstanding shares of the Common Stock of Caraco not held by Sun Pharma or Sun Global for per share consideration of $ 4.75 in cash representing a 5% premium over the most recent closing price of Caraco common stock. This offer is subject to the approval of Caraco Board and such other authorities as may be required and subject to completion of necessary compliances/formalities as may be required.
Nov 2010
15 Nov · Corporate action
Company has fixed November 26, 2010 as the Record Date for the purpose of ascertaining the names of the shareholders who would be entitled to receive 5 (five) equity shares of the nominal face value of Re.1 each for every 1 (one) equity of Rs.5 each held by them.
Oct 2010
30 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 51216 lacs for quarter ending on 30-SEP-2010 against Rs. 47439 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 34572 lacs for the quarter ending on 30-SEP-2010 against Rs. 20306 lacs for the quarter ending on 30-SEP-2009.30 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 137007 lacs for quarter ending on 30-SEP-2010 against Rs. 118517 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 50365 lacs for the quarter ending on 30-SEP-2010 against Rs. 45381 lacs for the quarter ending on 30-SEP-2009.18 Oct · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2010.
Sep 2010
24 Sep · Share Split
Board of Directors of the Company at its meeting held on September 24, 2010 has approved the proposal to sub-divide the nominal value of the equity shares of the Company from the nominal (face) value of Rs. 5 each to the nominal (face) value of Re. 1 each, subject to the approval of the members of the Company.
Aug 2010
11 Aug · Corporate action
Register of the Company will be closed from September 14, 2010 to September 24, 2010 (both days inclusive) for the purpose of payment of dividend for the year ended March 31, 2010.
Jul 2010
28 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 49888 lacs for quarter ending on 30-JUN-2010 against Rs. 40588 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 32263 lacs for the quarter ending on 30-JUN-2010 against Rs. 12151 lacs for the quarter ending on 30-JUN-2009.28 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 139970 lacs for quarter ending on 30-JUN-2010 against Rs. 78759 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 56432 lacs for the quarter ending on 30-JUN-2010 against Rs. 16384 lacs for the quarter ending on 30-JUN-2009.